Letters, Statements and Analysis - 2015

Communicating the importance of managed care pharmacy is a key part of AMCP’s work. Using AMCP policies as a basis for their work, AMCP staff and volunteers provide comments, analysis and testimony to Congress and other federal and state agencies on how proposed regulations and laws impact managed care pharmacy and the patients we serve.

 

2017

 

2016

 

2015

 

2014

 

2013

 

 

December

12/21/15

AMCP joins stakeholders in signing letter of support for H.R. 2841 - The Fair Access to Safe and Timely Generics Act (FAST Act). 

AMCP submits comments to CMS in response to the proposed rule Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2017 (CMS-9937-P) 

12/9/15

 

November

11/18/15

AMCP submits comments of concern to Iowa Division of Insurance regarding prior authorization regulations, encouraging the state to adopt NCPDP ePA standards in lieu of a paper form 

11/16/15

AMCP opposes Massachusetts HB 791 limiting step therapy by applying an exceptions process and limiting copays 

11/9/15

AMCP urges Senate Appropriations Committee to fully fund the Food & Drug Administration in FY 2016 

AMCP urges House Appropriations Committee to fully fund the Food & Drug Administration in FY 2016 

11/2/15

 

October

 
 

10/16/15

 

10/15/15
AMCP Provides Input on Texas Board of Pharmacy Strategic Plan for 2017-2021 

10/7/15

 

September

August

July

7/29/15

AMCP coalition supports Pharmacists Coordination of Services Report language in U.S. Senate HHS appropriations bill 

7/24/15

Bipartisan group of Senators send letter to HHS and FDA urging adoption of common INNs for biosimilars 

7/23/15

AMCP lends support to H.R. 1725, the National All Schedules Prescription Electronic Reauthorization Act (NASPER); sponsor Rep. Ed Whitfield (R-KY) and Energy & Commerce Subcommittee on Health 

7/16/15

AMCP supports Pharmacists Coordination of Services Report language in U.S. Senate HHS appropriations bill  

7/13/15

AMCP submits comments in response to FDA biosimilars Q&A document 

7/1/15

 

June

6/30/15

AMCP joins other pharmacy and PBM organizations, payers, and companies in signing letter to FDA in support of common INNs for biosimilars 

GPhA and Biosimilars Council Press Release - AMCP and other pharmacy and PBM organizations, payers, and companies ask FDA to support common INNs for biosimilars 

6/19/2015

AMCP opposes New Jersey A 2477 restricting the dispensing of biosimilars 

6/18/2015

AMCP asks Illinois Governor Bruce Rauner to veto SB 455 restricting the dispensing of biosimilars 

6/17/2015

AMCP requests modifications to California SB 671 restricting dispensing of biosimilars 

AMCP asks Louisiana Governor Bobby Jindal to veto HB 319 restricting the dispensing of biosimilars 

6/15/2015

AMCP requests modifications to Michigan HB 4437 restricting dispensing of biosimilars 

6/9/2015

AMCP opposes New York A.2834 restricting the use of step therapy 

AMCP opposes New York S.3419 restricting the use of step therapy 

6/4/2015

AMCP opposes New York A.6194 restricting the use of prescription drug mail order programs 

AMCP opposes New York S.2530 restricting the use of prescription drug mail order programs 

 

May

5/14/2015

AMCP asks U.S. House Energy & Commerce Committee for modifications to 21st Century Cures Act draft legislation 

AMCP signs joint letter with stakeholders in support of drug management programs in the 21st Century Cures Act 

5/11/2015

AMCP opposes Illinois HB 3549 restricting step therapy - Senate letter 

5/7/2015

AMCP joins multi stakeholder group to provide Congress with principles for drug management programs 

5/6/2015

AMCP opposes Ohio HB 116 addressing medication synchronization 

5/4/2015

AMCP asks Tennessee Governor Haslam to veto SB 984 restricting the dispensing of biosimilars 

 

April

4/30/2015

FDA response to AMCP letter on biosimilar naming and results of pharmacists' views on naming conventions 

4/28/2015

AMCP asks Washington Governor Inslee to veto SB 5935 restricting the dispensing of biosimilars 

AMCP opposes Louisiana HB 319 restricting the dispensing of biosimilars 

4/27/2015

AMCP joins stakeholders in seeking changes to FDA's proposed labeling change requirements 

4/22/2015

AMCP requests modifications to California SB 671 restricting the dispensing of biosimilars 

4/10/2015

AMCP asks Georgia Governor Deal to veto SB 51 restricting the dispensing of biosimilars 

4/8/2015

AMCP opposes Missouri SB 528 addressing medication synchronization 

4/7/2015

AMCP opposes Connecticut SB 1052 addressing MAC pricing 

AMCP supports Vermont HB 289 addressing biosimilar substitution 

4/6/2015

AMCP opposes Illinois HB 3549 restricting step therapy 

4/2/2015

AMCP requests modifications to Texas SB 542, which restricts dispensing of biosimilars 

AMCP requests modifications to Pennsylvania SB 514 PN 509, which restricts dispensing of biosimilars 

AMCP requests modifications to California SB 671, which restricts dispensing of biosimilars 

4/1/2015

AMCP urges HHS and FDA to adopt common INN names for biosimilars without prefixes or suffixes 

 

March

3/30/2015

Medicare Part D Program releases requirements for biosimilar products, March 2015 

3/25/2015

AMCP opposes Washington SB 5935, which restricts dispensing of biosimilars 

3/24/2015

AMCP opposes Minnesota HF 1060, which adds burdensome requirements on the use of prior authorization 

AMCP opposes Minnesota SF 934, which adds burdensome requirements on the use of prior authorization 

3/18/2015

AMCP requests modifications to Illinois SB 1611, which restricts dispensing of biosimilars 

AMCP opposes Minnesota HF 1038, which sets cost-sharing restrictions on abuse deterrent formulations 

AMCP opposes Minnesota SF 917, which sets cost-sharing restrictions on abuse deterrent formulations 

3/17/2015

AMCP opposes Arizona SB 1288 mandating requirements on medication synchronization 

AMCP requests modifications to Illinois HB 3519, which restricts dispensing of biosimilars 

AMCP opposes Tennessee HB 746, which sets cost-sharing restrictions on abuse deterrent formulations 

AMCP opposes Tennessee SB 601, which sets cost-sharing restrictions on abuse deterrent formulations 

AMCP opposes Washington SB 5695, which sets cost-sharing restrictions on abuse deterrent formulations 

3/16/2015

AMCP opposes Illinois SB 1802 restricting the use of abuse deterrent formulation prescription drugs 

AMCP opposes Illinois HB 2743 restricting the use of abuse deterrent formulation prescription drugs 

AMCP opposes North Carolina SB 197, which restricts dispensing of biosimilars 

AMCP opposes Texas HB 751, which restricts dispensing of biosimilars 

AMCP opposes Vermont SB 59 restricting the use of abuse deterrent formulation prescription drugs 

3/12/2015

AMCP opposes New Mexico HB 274 addressing medication synchronization 

3/9/2015

AMCP requests modifications to Tennessee SB 984, which restricts dispensing of biosimilars 

3/6/2015

AMCP comments to CMS on Draft 2016 Medicare Part D Call Letter 

AMCP Summary of CMS’s Draft 2016 Call Letter for Medicare Part D and Medicare Advantage

AMCP Summary of CMS’s 2016/2017 Final Rule and Issuers Letter for QHPs in Federally Facilitated Marketplaces  

AMCP supports New York SB 280 addressing collaborative drug therapy management 

AMCP requests modifications to Tennessee HB 572, which restricts dispensing of biosimilars 

3/4/2015

AMCP requests modifications to Maryland HB 887, which sets cost-sharing restrictions on abuse deterrent formulations 

AMCP requests modifications to Maryland SB 606, which sets cost-sharing restrictions on abuse deterrent formulations 

AMCP requests modifications to Oregon SB 147, which restricts dispensing of biosimilars 

3/2/2015

AMCP opposes Idaho HB 175, which restricts the dispensing of biosimilars 

AMCP requests modifications to Maryland HB 733, which restricts the dispensing of biosimilars 

AMCP requests modifications to Maryland SB 537, which restricts the dispensing of biosimilars 

 

February

2/27/2015

AMCP supports the Protecting the Integrity of Medicare Act of 2015 (PIMA) - U.S. HR 1021 

2/24/2015

AMCP and other pharmacy groups request modifications to Pennsylvania SB 514, which restricts dispensing of biosimilars 

2/20/2015

MCP opposes Kentucky HB 146 limiting copays 

AMCP opposes Kentucky SB 31 limiting copays 

2/19/2015

AMCP and other pharmacy groups encourage CMS to take action regarding pharmacist enrollment in the Medicare Program to ensure continued access to medications 

2/13/2015

AMCP opposes Colorado SB 15-71 (House version), which restricts dispensing interchangeable biologic products 

2/12/2015

AMCP opposes Colorado SB 15-123 addressing any willing provider 

AMCP opposes Kentucky SB 44 addressing medication synchronization 

AMCP opposes Missouri HB 198 addressing medication synchronization 

2/6/2015

AMCP opposes New Jersey S 1705, which restricts dispensing interchangeable biologic products 

AMCP supports Hawaii HB 254 creating a working group to study biosimilars 

AMCP opposes Georgia SB 51, which restricts dispensing interchangeable biologic products 

AMCP opposes Georgia HB 195, which restricts dispensing interchangeable biologic products 

2/5/2015

AMCP comments on U.S. House Energy & Commerce Committee draft 21st Century Cures Act 

AMCP opposes New Jersey A 2477, which restricts dispensing interchangeable biologic products 

AMCP opposes Hawaii SB 1244 addressing pharmacy audits 

 

January

1/29/2015

AMCP joins other health care experts in opposition to SB 15-071 

1/28/2015

AMCP opposes Virginia SB 1262 which includes mandated prior authorization provisions 

AMCP opposes Virginia HB 1942, which includes mandated prior authorization provisions 

AMCP opposes Colorado SB 15-071, which restricts dispensing interchangeable biologic products 

1/22/2015

AMCP urges FDA and HHS to consider INNs for biosimilars as first U.S. approval nears 

1/16/2015

AMCP supports biosimilars proposed rule in Idaho Senate Health & Welfare Committee 

AMCP supports biosimilars proposed rule in Idaho House Health & Welfare Committee 

1/12/2015

AMCP comments on the National Assn. of Insurance Commissioners' (NAIC) Health Benefit Plan Network Access and Adequacy Model draft act 

AMCP comments to CCIIO on the Draft 2016 Letter to Issuers in Federally-Facilitated Marketplaces  

1/7/2015

AMCP presents a public statement at the FDA Oncologic Drugs Advisory Committee meeting in support of the effort to approve biosimilar drugs under the BPCIA pathway 

1/6/2015

AMCP sends comments to the Iowa Division of Insurance with concerns about prior authorization proposed rule 

Content for class "break" Goes Here